United States, Las Vega (Nevada) //— As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Asthma therapeutics landscape based on different Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
The Asthma therapeutics market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies such as MRx-4DP0004 (4D Pharma), Fluticasone Propionate/Salmeterol Inhalation Powder (Cipla), Tezepelumab (AstraZeneca), among others.
“Asthma Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Asthma Market.
The Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Asthma Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Asthma and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Asthma Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Asthma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers 100+ Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Asthma Therapeutics Landscape
Current drug treatments for asthma include long-term control treatments, such as inhaled corticosteroids, long-acting beta-agonists, and oral medications. For acute episodes of Asthma, oral corticosteroids, beta-agonists, and inhaled bronchodilators are used. Environmental control measures (e.g., humidity regulation, vacuuming, and pest management) can reduce asthma exacerbations due to airborne allergens such as tobacco smoke, particulate matter, pollen, mold, or dust mites.
The Asthma therapeutics market dynamics are expected to transform due to the launch of pipeline therapies. As of now, there are approx. 100+ key companies developing therapies for Asthma. Currently, Avillion LLP has its Asthma drug candidates in the most advanced stage of clinical development.
The key companies in the Asthma Therapeutics Market include:
Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and many others.
Asthma Therapies covered in the report include:
– PT-027: Avillion LLP
– MM09-MG01: Inmunotek S.L.
– FP 025: Foresee Pharmaceuticals
– GB001: Gossamer Bio
– EDP1867: Evelo Biosciences, Inc.
– TQC2731: Chia Tai Tianqing Pharmaceutical Group
– Tezepelumab (AstraZeneca)
– Depemokimab (GlaxoSmithKline)
– MRx-4DP0004 (4D Pharma)
– Fluticasone Propionate/Salmeterol Inhalation Powder (Cipla)
And many more
Explore More About the Emerging Drugs and Key Companies: Asthma Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Asthma Current Treatment Patterns
4. Asthma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Asthma Late-Stage Products (Phase-III)
7. Asthma Mid-Stage Products (Phase-II)
8. Asthma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Asthma Discontinued Products
13. Asthma Product Profiles
14. Key Companies in the Asthma Market
15. Key Products in the Asthma Therapeutics Segment
16. Dormant and Discontinued Products
17. Asthma Unmet Needs
18. Asthma Future Perspectives
19. Asthma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Asthma Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
